368 related articles for article (PubMed ID: 23696264)
1. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y
Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
[TBL] [Abstract][Full Text] [Related]
4. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
5. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
6. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
7. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults.
Ruijter BN; Tushuizen ME; van der Helm D; Hew M; Reeven M; Vossen ACTM; Metselaar HJ; Alwayn IPJ; Dubbeld J; Polak WG; van Hoek B
Liver Transpl; 2024 Jun; 30(6):640-646. PubMed ID: 37698933
[TBL] [Abstract][Full Text] [Related]
9. A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.
Soriano-López DP; Alcántar-Fierros JM; Hernández-Plata JA; González-Jorge AL; Velázquez-Ramos S; Flores-Hernández MA; Fuentes V; Castañeda P; Nieto J; Sánchez JL; López B; Valencia-Mayoral P; Varela-Fascinetto G
Transplant Proc; 2016 Mar; 48(2):654-7. PubMed ID: 27110023
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
[TBL] [Abstract][Full Text] [Related]
11. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
12. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation : A Cohort Study.
Ruijter BN; Wolterbeek R; Hew M; van Reeven M; van der Helm D; Dubbeld J; Tushuizen ME; Metselaar H; Vossen ACTM; van Hoek B
Ann Intern Med; 2023 Feb; 176(2):174-181. PubMed ID: 36645888
[TBL] [Abstract][Full Text] [Related]
14. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
[TBL] [Abstract][Full Text] [Related]
15. Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.
Hayes D; Breuer CK; Horwitz EM; Yates AR; Tobias JD; Shinoka T
Pediatr Cardiol; 2015 Dec; 36(8):1748-53. PubMed ID: 26187515
[TBL] [Abstract][Full Text] [Related]
16. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.
Chinnock R; Webber SA; Dipchand AI; Brown RN; George JF;
Am J Transplant; 2012 Nov; 12(11):3061-8. PubMed ID: 23072522
[TBL] [Abstract][Full Text] [Related]
17. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract][Full Text] [Related]
19. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
Huang JG; Tan MYQ; Quak SH; Aw MM
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
